Next Article in Journal
Long-Term Immunogenicity upon Pertussis Booster Vaccination in Young Adults and Children in Relation to Priming Vaccinations in Infancy
Previous Article in Journal
Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 5
10.3390/vaccines10050692
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population

by
Javeria Aijaz
1,*,
Shakir Hussain
1,
Fouzia Naseer
1,
Fatima Kanani
2,
Sabiha Anis
3,
Samreen Sarfaraz
4,
Saima Saeed
5,
Hina Farooq
2 and
Saba Jamal
6
1
Molecular Biology Section, Pathology Department, Indus Hospital & Health Network, Karachi 75190, Pakistan
2
Chemical Pathology Section, Pathology Department, Indus Hospital & Health Network, Karachi 75190, Pakistan
3
Immunology Section, Pathology Department, Indus Hospital & Health Network, Karachi 75190, Pakistan
4
Infectious Diseases Department, Indus Hospital & Health Network, Karachi 75190, Pakistan
5
Pulmonology Department, Indus Hospital & Health Network, Karachi 75190, Pakistan
6
Pathology Department, Indus Hospital & Health Network, Karachi 75190, Pakistan
*
Author to whom correspondence should be addressed.
Vaccines 2022, 10(5), 692; https://doi.org/10.3390/vaccines10050692
Submission received: 23 March 2022 / Revised: 20 April 2022 / Accepted: 25 April 2022 / Published: 28 April 2022
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Browse Figures
Versions Notes

Abstract

Fifty five percent of the Pakistani population is still unvaccinated with the two-dose protocol of COVID-19 vaccines. This study was undertaken to determine the seroconversion rate and antibody titers following the two-dose BBIBP-CorV protocol, and to compare these variables in unvaccinated, COVID-19 recovered individuals (total n = 180) at Indus Hospital and Health Network, Karachi. Pseudotyped lentivirus antibody neutralization assays and SARS-CoV-2 IgG Quant II (Abbott) immunoassays were performed 4-8 weeks following the second dose of the BBIBP-CorV or PCR positivity/onset of symptoms of COVID-19. Seroconversion rate, using neutralization assays, in vaccinated individuals was lower (78%) than that in unvaccinated, COVID-19-recovered individuals with moderate to severe infection (97%). Prior PCR positivity increased serocoversion rate to 98% in vaccinated individuals. Immunoassays did not, however, reveal significant inter-group differences in seroconversion rates (≥95% in all groups). Log10 mean antibody neutralizing titers following the two-dose BBIBP-CorV protocol (IC50 = 2.21) were found to be significantly less than those succeeding moderate to severe COVID-19 (IC50 = 2.94). Prior SARS-CoV-2 positivity significantly increased post-vaccination antibody titers (IC50 = 2.82). Similar inter-group titer differences were obtained using the immunoassay. BBIBP-CorV post-vaccination titers may, thus, be lower than those following natural, moderate to severe infection, while prior SARS-CoV-2 exposure increases these titers to more closely approximate the latter.
Keywords: BBIBP-CorV; Sinopharm; COVID-19; Pakistan; pseudotyped; neutralizing; immunoassay; vaccine BBIBP-CorV; Sinopharm; COVID-19; Pakistan; pseudotyped; neutralizing; immunoassay; vaccine

Share and Cite

MDPI and ACS Style

Aijaz, J.; Hussain, S.; Naseer, F.; Kanani, F.; Anis, S.; Sarfaraz, S.; Saeed, S.; Farooq, H.; Jamal, S. Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population. Vaccines 2022, 10, 692. https://doi.org/10.3390/vaccines10050692

AMA Style

Aijaz J, Hussain S, Naseer F, Kanani F, Anis S, Sarfaraz S, Saeed S, Farooq H, Jamal S. Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population. Vaccines. 2022; 10(5):692. https://doi.org/10.3390/vaccines10050692

Chicago/Turabian Style

Aijaz, Javeria, Shakir Hussain, Fouzia Naseer, Fatima Kanani, Sabiha Anis, Samreen Sarfaraz, Saima Saeed, Hina Farooq, and Saba Jamal. 2022. "Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population" Vaccines 10, no. 5: 692. https://doi.org/10.3390/vaccines10050692

APA Style

Aijaz, J., Hussain, S., Naseer, F., Kanani, F., Anis, S., Sarfaraz, S., Saeed, S., Farooq, H., & Jamal, S. (2022). Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population. Vaccines, 10(5), 692. https://doi.org/10.3390/vaccines10050692

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop